120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Hoadley K, Rashid N, Spears P, Chic N, Krop I, Hillman D, Partridge A, Prat A, Carey L, Perou C. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials. Annals Of Oncology 2021, 32: s409. DOI: 10.1016/j.annonc.2021.08.401.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply